Monopar Therapeutics Inc., a biopharmaceutical company listed on Nasdaq as MNPR, based in Wilmette, Illinois, shared that new data regarding the neurological effectiveness and safety of their experimental treatment ALXN1840 for Wilson disease will be disclosed at the 150th American Neurological Association Annual Meeting on September 14-15, 2025. Presentations will be given by Dr. Matthew Lorincz, a Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan. The poster presentation can be accessed at https://www.monopartx.com/ALXN1840-ANA-2025-Poster-14-Sep-2025. Additionally, the oral presentation will be posted online at www.monopartx.com coinciding with Dr. Lorincz’s presentation on September 15, 2025.